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ABSTRACT: 
Advances in personalized medicine will require custom drug formulations and 
delivery mechanisms. Herein, we demonstrate a new type of personalized capsule 
comprising of printed concentric cylindrical layers with each layer having a distinctive 
functional drug component. Poly ε-caprolactone (PCL) with paracetamol (APAP) and 
chlorpheniramine maleate (CM), synergistic drugs commonly used to alleviate 
influenza symptoms, are printed as an inner layer and outer layer, respectively, via 
micro-scaled electrohydrodynamic (EHD) printing. Polyvinyl pyrrolidone (PVP) 
nanofibers are embedded as interlayers between the two printed PCL-drug layers using 
electrospinning (ES) techniques. The complete concentric cylindrical capsule with a 6 
mm inner diameters and 15 mm length can be swallowed for oral drug delivery. After 
dissolution of the PVP interlayer, the capsule separates in two, with inner and outer 
capsules for continuous drug dosing and targeting. Imaging was achieved using a 3T 
MRI system which allowed temporal observations of the targeted release though the 
incorporation of nanoparticles (Fe3O4). The morphology and structure, chemical 
composition, mechanical properties and biocompatibility of the capsules were studied 
in vitro. In summary, this new type of custom printed and electrospun capsule that 
enabled component separation, targeted drug release may advance personalized 
medicine via multi-drug oral delivery. 
 
KEYWORDS: composite capsules; capsule separation, controlled release; micro 
printing; multicomponent drugs.  
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1. Introduction 
  Compounding pharmacies and customized drug formulations have been advancing 
over the past few decades to meet demands of personalized medicine1-2. New medicine 
delivery systems have been invented which delivered drugs into the human body though 
the skin and nasal cavity3-4. However, oral formulations still remains the most widely 
used drugs delivery mechanism when dealing with treatment of chronic diseases and 
cancer therapy due to its convenience and efficacy5. Thus, developing methods to 
customize the release profiles of orally- administered drugs has become a research area 
that has attracted considerable interest6. A quick release profile supplies a sufficient 
dosage to deal with some acute conditions and a slow release profile delivers a steady 
dosage to treat chronic conditions while also decreasing the frequency of daily ingestion 
of pills7. Historically, the drug release profile was modified by changing the structure 
of the delivery capsule or modifying the concentration of excipients8-9. Also, 
multicomponent drugs were developed for improved targeting of disease inhibitors, 
which not only improves dosing convenience but also deals with complex disease 
comorbidities such as cardiovascular and cerebrovascular diseases synergistically10-12.  
  Traditionally, capsules are solid dosage forms in which the drug is enclosed within 
a soluble shell with diameters ranging from 5.06 mm to 8.15 mm, and a capsule length 
between 12.1 mm and 19.8 mm. Capsules have the advantage that they are easily 
administered, they can cover up unpleasant drug odors and taste, and dissolve rapidly13-
15. However, typically, capsules can only be loaded with compatible drugs and this 
limited the development of multicomponent medicines to a great extent16-17. 
 4 
Furthermore, these mass produced capsules generally had a uniform dosage and release 
profile although high concentrations of drugs, such as bromide and aspirin, may 
stimulate the gastric mucosa which may lead to adverse side effects18-19. For example, 
a proper concentration of phenytoin sodium can be applied to the treatment of 
arrhythmia. Whereas, the a high concentration of phenytoin sodium in blood plasma 
concentration may lead to toxic effects20. Therefore, a specific drug dose and release 
profile are needed for improved efficacy and to minimize side effects due to individual 
differences in patients.  
  3D printing has been applied to tissue regeneration, wound healing, organ 
scaffolding and in pharmacology duo to its convenience and commercial availability21-
24. Fused deposition modeling (FDM), a form of 3D printing, has been reported and 
applied to the manufacturing of pharmaceuticals to realize customized production in 
the treatment of many diseases25-26. However, the high temperature of the printing 
nozzle during operation is not compatible with many thermosensitive drug compounds. 
Also, precision control of the millimeter-scale-diameter filament used in FDM 3D 
printing remains challenging in terms of accurate dosage control and the resulting drug 
release behaviors. In contrast, Electrohydrodynamic (EHD) 3D printing has advantages 
in terms of having a higher controllable resolution (e.g. the diameter of the filament can 
be on the micrometer or even nanometer scale) and is unheated27-28. 3D microstructures 
with drugs or bioactive compounds can be prepared in an ambient environment and the 
process can be done in a single step29. A range of various polymers with viscosities 
ranging from 1 mPa·s to ~10,000 mPa·s can be used as the carrier suspension to form 
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a small jet from the nozzle orifice via an applied electrical field force in order to achieve 
ultrahigh resolution structures30. The formation of filaments and their resulting 
deposition accuracy at these smaller sizes can be controlled by parameters such as the 
applied voltage, the working distance, and the interactions of the solution properties31-
32. In addition, the electrospinning (ES) technique has been applied widely to engineer 
micrometer and nanometer scale fibers for encapsulation applications and tissue 
engineering of scaffolds33-34. A non-woven mat containing random fiber orientations can 
be quickly fabricated by the ES technique. 
  In this work, a new type of cylindrical, multicomponent capsule was demonstrated 
which integrated EHD 3D printing and ES techniques for the first time. This capsule 
does not have the traditional capsule weakness of a burst release in the gastrointestinal 
tract after ingestion. Specific release profiles can be designed via selecting appropriate 
inert materials and patterning the various structures to increase the desired surface area. 
PCL was selected as the carrier material, with paracetamol (APAP) and 
chlorpheniramine maleate (CM) as the active drugs embedded into these outer and inner 
layers, respectively. Polyvinyl pyrrolidone (PVP) fibers are randomly electrospun and 
embedded as an interlayer between the two printed PCL layers. Once the PVP interlayer 
dissolves, the inner layer and outer layer of PCL membrane separate. By tracking the 
motion of encapsulated Fe3O4 nanoparticles in the PCL fibers, one part of the separated 
capsule containing Fe3O4 nanoparticles can travel to a specific location and release 
drugs with the assistance of an external magnetic field in order to realize the targeted 
therapeutic delivery. A multicomponent drugs capsule was designed to separate in order 
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to achieve that dosage control over each component drug after separation. To the best 
of our best knowledge, this is the first reported fabrication of a separating capsule which 
contains multicomponent drugs with different dosage profiles for oral delivery. 
 
2. MATERIALS AND METHODS 
2.1. Materials.  
Poly ε-caprolactone (PCL, Mw=80000 g/mol) and polyvinyl pyrrolidone (PVP, 
Mw=1300000 g/mol) were obtained from Sigma-Aldrich (St Louis, USA.) 
Dichloromethane (DCM), dimethyl formamide (DMF), ethyl ethanol (EtOH) and 
phosphate buffered saline (PBS pH=7.4) were obtained from Sinopharm Chemical 
Reagent Co. Ltd (Beijing, China.) Chlophrnamine maleate (CM) and paracetamol 
(APAP) were purchased from Aladdin Biochemical Technology Co, Ltd (Shanghai, 
China.) Paracetamol (APAP) is a common non-steroidal drug for anti-inflammatory 
antipyretic treatment of symptoms of the influenza and toothache pain while 
chlorpheniramine maleate (CM) is an antihistamine which is a H1 receptor antagonist 
and is used for the treatment of rhinitis, sternutation, and other symptoms of mucosa 
allergy. Both APAP and CM were selected as model drugs due to their synergistic effect 
on alleviating influenza symptoms. Fe3O4 nanoparticles were obtained from HWRK 
Chem (Beijing, China). Unless otherwise noted, all materials were used directly without 
any further purification and disposition.  
2.2. Solution preparation  
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PCL was dissolved into DCM and DMF (93:7 v/v) to prepare PCL solution (w/v = 
22%) via magnetic stirring for 3 hours and rested for 1 hour at an ambient temperature 
of 25 ℃ to dissolve completely without bubbles. CM (w/w =0.5%) and APAP (w/w 
=5%) were dissolved into the PCL solution separately. PVP was dissolved into EtOH 
(18 wt%) with magnetic stirring for 5 hours at a speed of 150 rpm. 1% (w/w) Fe3O4 
nanoparticles were added into the PCL solution and magnetically stirred for another 
two hours.  
2.3. Fabrication of cylindrical capsule 
The cylindrical capsule has a 6 mm inner diameter and is 15 mm in length. It was 
fabricated by combining 3D printing and ES technology with a cylindrical collector. 
Both the inner layer and outer layer of the capsule were fabricated via EHD 3D printing 
using the same parameters. The process for capsule fabrication is shown in Figure 1.  
The EHD 3D printing system (Figure 1(a)), which includes a syringe pump, high 
voltage supply, X-Y motion translation platform and cylindrical collector, is used to 
fabricated the inner layer and outer layers of the cylindrical capsule. During EHD 3D 
printing, the flow rate was set at 0.3 ml/h and the voltage was set at 2.5-2.7 kV. The 
distance between the metal needle and the cylindrical collector was set at 3-4 mm. The 
rotation speed of cylindrical collector was set at 150 rpm and the X-axis moved at 6 
mm/s between two points whose distance was 15 mm apart and this was repeated 150 
times. The interlayers were fabricated via electrospinning (Figure 1(b)) with the same 
equipment as used for EHD 3D printing at a flow rate of 0.8 ml/h for the PVP solution 
and at voltages from 8 - 10 kV. The distance between the metal needle was set at 10 - 
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15 mm and the cylindrical collector was rotating at 600 rpm. The fabrication of the 
complete cylindrical capsule, as illustrated in Figure 1(c) has a PVP interlayer that 
separates the PCL-APAP and PCL-CM drug layers.  
 
Figure 1. Schematic illustration of the experimental setup, fabrication process and 
structure of the composite layers rolled into concentric cylinders to fit inside an oral 
delivery capsule. The fabrication process includes (a) inner and outer PCL layers 
fabricated using EHD printing, (b) electrospinning of the PVP interlayer, and (c) the 3 
fiber layers are combined into a composite concentric cylinder. 
2.4. Morphology characters of the Cylindrical capsule 
Optical microscopy (OM) (Pheonix BMC503-ICCF, China) and scanning electron 
microscopy (SEM) (S-4800, Hitachi, Japan) were used to examine the surface 
morphology of the fibers. Each sample was coated with a thin-film layer of gold via 
sputter coating for 3 minutes before SEM imaging. All the microsopy images were 
scaled using ImageJ software (National Institutes of Health, USA). 
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2.5. Fourier transform infra-red (FTIR) spectroscopy 
Fourier transform infra-red (FTIR) spectroscopy (Ir affinity 1, Shimadzu, Japan) was 
used to determine the chemical composition of the capsule via the KBr pellet pressing 
method. 2 mg of each component (pure PCL, pure PVP, pure CM, pure APAP, PCL 
containing CM, PCL containing APAP and the whole capsule) was mixed with 200 mg 
KBr and grinded down and compressed into transparent pellets under 12 MPa of 
pressure. Then all the pellets were scanned with FTIR between 4000 cm-1 to 450 cm-1. 
Each spectrum was obtained from the average of 20 scans. 
2.6. Raman spectroscopy 
Raman spectroscopy and mapping was performed to characterize the distribution of 
the APAP and CM in the printing fibers. In situ printed fibers with 50 layers were 
evaluated using a laser confocal raman spectrometers (LabRAM HR Evolution, Horiba 
Jobin Yvon, France) using a 532 nm argon ion laser with a peak power of 300 mW. 
Surface areas of 100 μm * 100 μm (X-Y plane) of the fibers were scanned with 20 x 20 
pixels resolution in X and Y using a 50X objective35. Spectra was scanned from 200 to 
1800 cm-1 with 10 s exposure time and 1 s accumulation time. Labspace 6 software 
(Horiba, France) was used to generate false color maps with characteristic peaks of 454 
cm-1 and 1258 cm-1 for APAP and 1094 cm-1 and 1594 cm-1 in wavenumber for CM in 
order to identify characteristic Raman peaks36-37.  
2.7. Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) tests were carried out to examine the thermal 
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properties of the printed cylindrical capsules using a DSC 1/400 (METTLER-TOLEDO, 
Switzerland). DSC tests were performed under a nitrogen atmosphere. The capsule and 
its components underwent temperature changes ranging from 25℃ to 260℃ with a 
change rate set at 10 ℃/min. 
2.8. X-ray diffraction 
X-ray diffraction (XRD) tests were carried out with a X-ray diffractometer (Gemini 
A Ohra, Oxford, UK) to check the crystal texture of the capsule components. The 
capsule was scanned over a range from 5° to 60°over 2θ with step a change of 0.02° at 
40 mA and 40 kV. 
2.9. Magnetization curve test 
The magnetization curve of samples with different content of Fe3O4 nanoparticles 
was monitored via vibration sample magnetometer (Versalab, Quantum Design, Inc, 
San Diego, USA) at 300K under magnetic field strengths between -10000 Oe and 10000 
Oe. This was done to obtain material properties for subsequent MRI analysis. 
2.10. In vitro MRI testing 
MRI images were obtained from a 3T MRI system (Magnetom prisma; Siemens 
Healthcare, Erlangen, Germany). Centrifuge tubes containing agar gel to mimic human 
body and capsule samples with different thicknesses and inner diameters were put into 
the head/neck coil region which has 20 channels. For agar gel preparation, 1g agar was 
mixed with 100 mL DI water, then heated to 100 ℃ and cooled. This temperature 
cycling was carried out several times to obtain a homogeneous agar gel. For the samples, 
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cylindrical layers with diameters of 6 mm and 10 mm, respectively, with 1% Fe3O4 
nanoparticles embedded in the outer and inner PCL layers were printed using the 
cylindrical collector. X-axis scans were repeat 150 and 300 times, with respect to the 6 
mm and 10 mm cylindrical capsules, to investigate the effect of the dimensions of the 
PCL fibers on MRI imaging.  
2.11. Mechanical test 
Compressed mechanical tests were performed to identify the mechanical properties 
of the capsules with respect to different interlayer thicknesses and total cross-sectional 
area. This information is listed in Table 1. Each sample was separately tested under 
uniaxial compression along the longitudinal and radial axis. A universal material testing 
machine (Zwick Roell Z020, Zwick, Germany) was employed with a 500N mechanical 
sensor. Samples were compressed to 80% of either their original longitudinal or radial 
capsule dimensions, respectively, at a rate of 5 mm/min. Stress, s, is calculated from 
the following equation 1: σ = #$%                                                            (1) 
Where F is the applied compression force and SA is the change in the cross-sectional 
area of the samples38.  
Strain is calculated using equation 2: ε = ∆(()                                                            (2)                                                                                   
Where ∆𝐿 is the change in the length and 𝐿+ is the original length of the sample. 
The (Young’s) modulus is obtained from the slope of the stress-strain curve in the 
linear region between 5% to 10% compression displacement with respect to the original 
 12 
size of the sample, as defined in equation 3:  Modulus = 23 = #∗()$%∗∆(                                                (3) 
Measurements for each sample were performed at least 3 times.  
Table 1. Structural configuration of different samples used for testing of mechanical 
properties and for in vitro drug release. 
Sample (cross-
sectional area 
mm2) 
Inner layer interlayer Outer layer 
S1 (9.06) PCL-APAP 
fiber 
-- PCL-CM fiber 
 
S2 (20.87) PCL-APAP 
fiber 
1h electrospinning PVP 
mat 
PCL-CM fiber 
S3 (23.20) PCL-APAP 
fiber 
2.5h electrospinning 
PVP mat 
PCL-CM fiber 
 
S4 (26.38) PCL-APAP 
fiber 
2.5h electrospinning 
PVP mat 
Double PCL-
CM fiber layers 
 
2.12. Separation tests 
Separation of the different cylindrical layers comprising the capsule is an important 
function of these multicomponent printed structures and has a direct impact on the 
individual drug release profiles. Separation tests were performed to identify the 
influence of the thickness of the electrospun interlayer and the rotation speed of the 
liquid environment on the separation efficiency. Four capsules, labeled from S1 to S4, 
with different thicknesses of the electrospun interlayer were obtained by changing the 
electrospinning times from 1h (0.82 mm thickness), 1.5h (1.13 mm thickness), 2h (1.41 
mm thickness) and 2.5h (1.77 mm thickness). The four different capsules were 
immersed in 50 mL PBS solution at a stirring speed at 500 rpm using a magnetic stirrer. 
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In addition, capsules prepared at 1.5h were examined at three other rotational speeds, 
specifically at 300 rpm, 500 rpm, and 700 rpm, to characterize the separation time. The 
timer starts when the capsule was immersed into the PBS solution and ends with 
separation between the inner layer and outer layer of the capsule. Three capsule samples 
were test in each group. 
2.13. Interlayer mass loss test during separation 
In order to better understand the influence of the thickness of the interlayer on the 
separation, mass loss tests were carried out. Again, four groups of capsules were 
fabricated with different interlayer thicknesses (1, 1.5, 2 and 2.5h) and weighed (𝑀). 
Each capsule was immersed in a PBS solution with a stirrer rotating at 300 rpm. After 
a certain elapsed time 𝑡𝑖 (where ti = 0.5, 1, 3, 5, and 10 min. respectively), the 
capsule was collected and dried. The mass is recorded as 𝑀𝑡𝑖. Then, the dried capsule 
was immersed in DI water while stirring for 3 hours at 300 rpm following by drying 
and weighed again. This mass is recorded as M+. The percentage of the mass loss 
during separation is calculated using equation 4: Percentage	of	the	PVP	mass	loss % = GHGIJGHG) ∗ 100%                  (4) 𝑀 −MNO  is the mass after the PVP dissolved after a specific elapsed time 𝑡𝑖 . 		𝑀 −𝑀+ is the mass after the PVP dissolved completely. 
2.14. Drug release test 
Drug release tests were performed to examined the drug release profiles from the 
various capsules. In order to mimic the gastrointestinal environment encountered by 
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orally administered drugs, three different capsules with different thickness were each 
immersed in simulated gastric fluid (pH=1.7) and simulated intestinal fluid (pH=7.4), 
respectively. Each sample was immersed into 10 ml of simulated gastric fluid and 
incubated at 37 ℃ in a HZ-8801K thermostatic oscillator (Taicang Science and 
Education Factory, China) with a 200 rpm shaking speed to simulate oral condition. 3 
ml of simulated gastric fluid solution containing any dissolved capsule layers was 
collected and examined by ultraviolet (UV) spectra measurement (UV-2600 
spectrophotometer, Shimadzu, Japan) at set intervals. Then, 3 mL of fresh simulated 
gastric fluid was added into the drug release solution. After 120 mins, any remnants of 
the capsule layers were transfer into 10 mL of simulated intestinal fluid solution and 
the above UV measurement steps were repeated. The UV absorption values of CM and 
APAP were selected at wavelengths of 243 nm and 262 nm, respectively. Each group 
had three samples. The release rate of the drugs were calculated using equation 5: 
 Drugs	release	rate	(%) = RNRG ∗ 100%                                (5) 𝐶𝑡 is the drug mass released from the capsule during an elapsed time t. 𝐶𝑀 is the 
maximum mass released from the capsule. 
In order to determine the drug release mechanism, the drugs release rate was fitted to 
several models such as zero-order, first-order, Higuchi, Korsmeyer-Peppas and Hixson-
Crowell models. 
2.15. Biocompatibility and cytotoxicity  
In order to determine the biocompatibility of the capsules, mouse fibroblast cells 
(L929) were used to test for cytotoxicity in vitro. MEM medium with 10% FBS and 
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1% antibiotic-antimycotic solution were used to culture the L929 cells at 37℃ in 5% 
CO2.  
Before each experiment, all samples were sterilized under a UV light for 4 h. 
Subsequently, the printed PCL-APAP fibers, the PCL-CM fibers and the capsule were 
added into the MEM medium at a concentration of 3 mg/mL, and then added into a 
culture dish with 0.2 mL of L929 cells and 2 mL of MEM medium for 2 days.  
After culturing for 2 days, L929 cells were fixed using 4% paraformaldehyde and 
permeabilized using 0.1% Triton X-100. The cell cytoskeletons and nuclei were stained 
using Alexa Fluor 546 phalloidin and 4’,6’-diamidino-2-phenylindole, respectively. 
The morphology and distribution of cells was imaged using a fluorescent microscope 
(Nikon Ti-S, Japan).   
A CCK-8 assay was applied to quantify cytotoxicity of L929 cells after culturing with 
the components of the capsule. A 200 μL cell suspension was added into a 96-well plate 
and cultured 7 h with 1 mg of PCL-APAP fibers, 1 mg of PCL-CM fibers and the 
capsule, respectively. Then, 20 μL of CCK-8 solution was added into each well and 
cultured according to assay instructions. A microplate reader (Multiskan Go, Thermo 
Fisher Scientific, USA) was used to read the absorbance at 450 nm. Cell viability was 
calculated using the following equation: Cell	viability % = %YH%Z%[H%Z ∗ 100%                                     (6) 
Where As is the absorbance of the sample groups, Ac is the absorbance of control 
group (containing L929 cells and the CCK-8 solution), and Ab is the absorbance of the 
blank group without samples, L929 cells and CCK-8 solution.  
 16 
2.16. Statistical analysis 
All experiments were carried out at least three times and data is shown as the mean ±  standard deviation (n ≥ 3). Statistical analyses were performed using SPSS 
Statistical v18 software (IBM, UK.). If the result of Student’s t-test is *p < 0.05, the 
statistical difference is determined to be statistically significant.  
 
3. Results and Discussion 
3.1. Design and fabrication of capsules    
The capsule fabrication process and schematic illustrations of the completely 
assembled capsule are shown in Figure 1. Capsules with 6 mm outer diameters and 
15mm in length were designed and fabricated. The inner layer and outer layers of the 
capsule consisting of PCL-APAP fibers and PCL-CM fibers, respectively, were 
prepared using a stable cone jet during EHD 3D printing at voltage from 2.5-2.7 kV. 
The PVP interlayer was generated using a stable cone jet during electrospinning at 
applied voltages from 8-10 kV. Deposition of the PVP layers was fabricated at varying 
times of 1 hour, 1.5 hours, 2 hours and 2.5 hours. Figure 1c shows the integration 
process and a cross-sectional illustration of the complete capsule containing an inner 
layer of PCL-APAP fibers, an interlayer of PVP fibers and an outer layer of PCL-CM 
fibers.  
Figure 2 shows the OM and SEM images of the capsule components generated using 
EHDP and ES methods. The arrangement and deposition of the inner layer PCL fibers 
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are shown in Figure 2(a), 2(b) and 2(c). The printed fibers are well-aligned with fiber 
diameters ranging from 17.51±5.77 µm. Many holes can be observed on the surface of 
the PCL fibers in the high magnification SEM image (Figure 2(c)) due to solvent 
volatility39. The electrospun interlayer of PVP fibers are shown in Figure 2(d), 2(e)) and 
2(f). These fibers have uniform dimeters of 1.65±0.17 µm and a smooth surface. OM 
and SEM images of the outer PCL-CM layer of the complete capsule are shown in 
Figure 2(g) and 2(h), respectively. The diameter of the outer layer (comprised of PCL-
CM fibers) is 20.35±7.76 µm and is larger than the diameter of the inner layer (of PCL-
APAP) fibers. This is due to the shorter distance between the needle and the fiber 
deposition area. The insert picture of Figure 2(h) presents a cross-section of the capsule 
which clearly shows the multi-layered deposition of the concentric cylindrical capsule 
containing an inner layer of PCL-APAP fibers, the interlayer of PVP fibers, and the 
outer layer of PCL-CM fibers. It is noted that the thicker interlayer thickness may affect 
the printing of the outer layer due to the change in the local electric field gradient. 
However, the whole process was stable during EHD printing and electrospinning, 
yielding a final capsule product as shown in Figure 2(i).  
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Figure 2. OM and SEM images of components and the integrated capsule. (a) OM 
images and (b) SEM image of the EHD printed PCL-APAP fibers and (c) fibers at 
higher magnification; (d) OM images and (e) SEM image of electrospinning PVP fibers 
and (f) fibers at higher magnification; (g) OM images and (h) SEM image of the EHD 
printed outer layer (PCL-CM) and a cross-sectional image of the integral capsule (inset); 
(i) Image of the complete capsule. 
 
3.2. Raman spectra results 
The distribution of drugs in the printed fibers was non-destructively examined via 
their Raman spectra40-41. 50 layers of printed fibers of PCL-APAP and PCL-CM were 
tested. Figure 3 is a Raman mapping over a 100 * 100 μm2 area of the PCL-APAP and 
PCL-CM fibers. The color in the map indicates the drug content. The change in color 
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ranging from blue to red indicates the relative concentration of a drug. An OM image 
of the PCL-APAP fiber is presented in Figure 3(a), while false color mappings of the 
PCL-APAP fiber with characteristic Raman peaks for APAP37 at 1258 cm-1 and 458 cm-
1 are shown in Figure 3(b) and Figure 3(c), respectively. The change of intensity from 
blue to red in the mapping scale is mostly due to the spatial distribution of the different 
concentrations of the APAP present and the (blue) background area indicates PCL. The 
Raman spectrum shows that the APAP is distributed homogenously in the printed fibers. 
The yellow and green scope of region indicted the APAP may remain amorphous state41. 
However, OM (Figure 3(d)) image and Raman false color mapping of PCL-CM fiber 
with nearby character peaks 1094 cm-1 (Figure 3(e)) and 1594 cm-1 (Figure 3(f)) of CM42. 
Similar result displaying the distribution of the CM (red, yellow and green regions) is 
presented in the false color mapping of the PCL-CM fiber. These results confirm the 
successful drug encapsulation in micro scaled printed fibers and their drugs distribution 
is homogeneous.  
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Figure 3. Raman false color mapping of PCL-APAP fibers and PCL-CM fibers. OM 
image (a) and false color mapping of PCL-APAP fibers with characteristic peaks at 
(b) 1258 cm-1 and (c) 454 cm-1 for APAP. OM image (d) and false color mapping of 
PCL-CM fibers with characteristic peaks at (e) 1094 cm-1 and (f) 1594 cm-1 of CM. 
 
3.3. Fourier transform infrared spectroscopy, DSC thermograms and XRD 
analysis 
FTIR spectroscopy was used to confirm the chemical composition of the capsule 
components before and after fabrication using printing and electrospinning. Figure 4(a) 
shows the FTIR spectra of pure PCL, pure PVP, pure APAP and pure CM. Pure PCL 
polymer peaks are observed at 1725 cm-1 , which is due to carbonyl (c=o) groups43. 
Other peaks, such as at 2868 cm-1 and 2949 cm-1, arise from methylene (CH2) groups. 
The presence of bands at 1643 cm-1 arise from C=O groups, 1018 cm-1 and 1076cm-1 
are due to C-N stretching and the N-OH complex at 1288 cm-1 confirm the existence of 
pure PVP and within the fabricated capsule44. For pure APAP, the characteristic peaks 
are present at 3200 cm-1 due to OH and NH stretching along with secondary bands at 
1700 cm -1 and 1500 cm-145. For pure CM, the characteristic peaks at 3012 cm-1 are due 
to C-H stretching. The peaks at 1205 cm-1 and 1151cm-1 arises from C-N vibration, and 
peaks at 1473cm-1 are a result of C-C multiple bond stretching46. Figure 4b is a FTIR 
spectrum of PCL-APAP, PCL-CM and the composite capsule. Some characteristic 
peaks for APAP and CM were present in the composite structure. This shows that the 
fabrication of the composite capsule with multicomponent drug layers was achieved via 
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integration of EHD printing and electrospinning. 
 
Figure 4. (a) FTIR spectrum of pure PCL, pure PVP, pure APAP and pure CM, (b) 
FTIR spectrum of the EHD printed PCL-APAP fibers and PCL-CM fibers, and the 
combined capsule, (c) DSC thermograms of graphing the individual raw materials and 
the composite capsule, (d) XRD results comparing the individual raw materials and the 
composite capsule. 
Figure 4(c) presents DSC thermograms of the capsule components and the complete 
capsule. The glass transition temperature of PCL, APAP and CM are 57℃, 156℃ and 
130℃, respectively. Comparing each component of the capsule to the complete capsule, 
the complete capsule only displays an endothermic peak for PCL but has no peaks 
corresponding to APAP and CM which confirms that these drugs remain in an 
amorphous state47-48.  
XRD analysis was performed in order to check the physical structure of the capsule 
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components before and after printing and electrospinning. Figure 4(d) presents the 
XRD curves for pure PCL, pure PVP, pure APAP, pure CM and the complete capsule. 
For pure PCL, two strong Bragg diffraction peaks are visible at angles 2θ = 21.4° and 
23.8° which is due to the diffraction of the (110) and (200) lattice planes of PCL49-50. 
The measured XRD pattern shows a wide signal for pure PVP which indicates an 
amorphous state51. The crystallinity of the CM is seen in its unique XRD pattern with 
several sharp peaks at 13°, 19.3°, 25° and 25.7°52-53. The APAP has two forms: a 
monoclinic form and orthorhombic form. The XRD pattern for the APAP shows several 
peaks with Bragg angles at 12.14°, 15.58°, 18.2°, 23.52° and 24.38°. These results show 
that the APAP used was in its monoclinic form because its orthorhombic form has 
another characteristic peak at Bragg angle of 24.03°, which is missing in this figure37, 
54. However, the complete capsule only has weak peaks for PCL without the prominent 
peaks for APAP and CM. This confirmed again that the APAP and CM were in 
amorphous state after complete capsule fabrication. It should be noted that many 
crystalline drug compounds are poorly water-soluble and hence have non-ideal 
bioabsorption profiles. Amorphous forms of a drug exist at a higher energy state with 
increased molecular mobility compared to its crystalline form which is desirable for 
increasing the rate of bioabsorption into a tissue55. In addition, the amorphous state has 
advantages of higher solubility and chemical stability after mixing with polymers for 
therapeutic delivery56.  
 
3.4. Magnetization curves and MRI imaging  
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In order to physically track the behavior of the complete capsule in situ, Fe3O4 
nanoparticles were introduced into the PCL layers of the capsule. This allows for 
multifunctional uses of the capsule such as for targeted drug release using an externally 
located magnet, and as a magnetic resonance tracer. Figure 5(a) displays the 
magnetization curves of the complete capsules with different Fe3O4 nanoparticle 
concentrations. All these “s” curves pass through the graph origin point without 
hysteresis. As the applied magnetic field increases, the magnetic moment (Y-axis) of 
the complete capsule also increases. As expected, the magnetic moment increased with 
increased concentration of Fe3O4 nanoparticles which means that increasing the mass 
of Fe3O4 nanoparticles will improve the magnetic response to external magnetic fields. 
Figure 5(b) to 5(g) show the capsule preparation for T1 graphing and T2 imaging 
using the MRI system. Capsules with different diameters (6 mm and 10 mm) and PCL 
layer thicknesses (by repeated printing 150 and 300 times, respectively) and containing 
1% Fe3O4 nanoparticles in the outer and the inner PCL layers were prepared to 
investigate the effect of the diameter and thickness of these PCL fiber capsules on MRI 
imaging. The outline of the complete capsule can be observed in the MRI system and 
more details are observed by increasing the thickness (printing times) of the capsule. 
However, no major difference can be observed in the MRI image when the capsule 
diameter is increased from 6 mm to 10 mm. This can be due to the resolution of the 3T 
MRI system. Nevertheless, the basic capsule configuration used for drug delivery in 
this paper is also sufficient to be used as a magnetic resonance imaging tracer. 
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Figure 5. (a) Magnetization curves for the complete capsules with different Fe3O4 
nanoparticles concentrations: 1%, 2% and 3% of the PCL mass. (b) and (c) are images 
of the capsule sample prepared for MRI testing. (d) and (f) are different views from T1 
imaging: the three samples from top to bottom have a diameter of 6 mm with 150 times 
printing, a diameter of 6 mm with 300 times printing, and a diameter of 10 mm with 
300 times printing, respectively. (e) and (g) are different views of T2 imaging: the three 
samples show, from top to bottom, have a diameter of 6 mm with 150 times printing, a 
diameter of 6 mm with 300 times printing, and a diameter 10 mm with 300 times 
printing.  
 
3.5. Mechanical test 
Figure 6 shows the complete capsule compressed in different directions and the 
corresponding measured mechanical properties. The sample parameters are listed in 
Table 1. Mechanical tests were performed in both the longitudinal and radial direction 
of the capsules as shown in Figure 6(a) and (d). Tests in the longitudinal direction 
confirms that the Young’s modulus increased with an increase in either the printed PCL 
 25 
or electrospun PVP fibers (Figure 6(b)). The result in the radial direction test shows the 
same trend. However, as shown in Figure 6(e) the modulus of sample S1 is obviously 
higher than the other samples during testing in the radial direction because the cross-
sectional surface area of sample S1 is less than the other samples. This is consistent 
with Equation 3 where the cross sectional area affects the stress calculation and the 
resulting modulus. Furthermore, the PVP interlayer of the cylindrical capsule may 
reduce the strength of the capsule during radial-direction compressed test since the PVP 
polymer has weaker mechanical properties when compare to the PCL polymer. 
However, the tests in the longitudinal direction test do not show the above result, as 
seen in Figure 6(b) and the rate of change of the stress in the radial direction is lower 
than in the longitudinal direction during the first 10% of compression. During 
longitudinal compression, the thickness of the interlayer PVP effectively increased, and 
the capsule eventually failed due to buckling because of the lower material strength of 
the PVP. 
 
Figure 6. Mechanical testing of the complete capsules. (a) Photographs of capsules 
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during compressive tests in the longitudinal direction. (b) Calculated stress–strain 
curves in the longitudinal direction for each sample capsule. (c) The Young’s modulus 
due to longitudinal compression of each sample. (d) Pictures of a capsule during 
compressive testing in the radial direction. (e) Stress–strain curves for each sample 
under compressive testing in the radial direction. (f) Compressive modulus for each 
sample in the radial direction.  
 
3.6. In vitro separation process 
This separating composite capsule has the inherent ability to precisely control the 
release of each component drug. In order to verify this capability, in vitro testing was 
performed to observe separation of a composite capsule with a PVP interlayer that was 
ES for 2.5h yielding an approximately 1.7 mm thickness. Figure 7(a) shows the 
separation process for sample S3 at different time intervals from 0 s to 295 s. The 
capsule sample was immersed in a 100 ml beaker containing 50 mL PBS solution while 
being magnetically stirred at 100 rpm. The whole separation process was finished in 
169 s and the complete dissolution of the PVP finished at 295 s. A time-elapsed video 
of the separation pictured in Figure 7(a) is available as Video S1. It was interesting that 
during the separation process, the PVP did not dissolve from the capsule slowly, but the 
bulk of the PVP sheet rapidly separated from the capsule. This might be due to the 
centrifugal force on the PVP interlayer after water absorption. When there was enough 
space between the inner layer and outer layer, the PVP interlayer was ejected from the 
capsule and then the inner layer and outer layer successfully separated.  
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Regulation and controlled movement of each component drug layer after separation 
was achieved by adding Fe3O4 nanoparticles and an external magnetic field. The 
magnetic response of these embedded nanoparticles provided a powerful method to 
control the drug release and drug tracking with MRI.57-58 Figure 7(b) shows the process 
of magnetic attraction after two layer separation. The separated capsule containing the 
printed outer PCL with embedded Fe3O4 nanoparticles can be seen travelling quickly 
from the left to right sides of the beaker under an applied external magnet field, in a 
beaker containing 30 mL PBS solution, as shown in Figure 7(b) and Video S2. Note 
that the inner layer without any nanoparticles remained stationary. This travel distance 
was covered within 3 s at a velocity of 6.7 mm/s. Thus, starting with a single composite 
capsule, after capsule layer separation another new method for targeted delivery has 
been demonstrated via an applied external magnetic field.   
 
Figure 7. Separation process (a) of the composite cylindrical capsule (around 1.7 mm 
thickness) with a stirring speed at 100 rpm in 50ml PBS solution and the magnetic-field 
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induced translation process (b) outer layer containing nanoparticles travels from left to 
right in a 30 ml PBS solution. 
 
In order to further investigate the effect of other variables on capsule separation, the 
effects of electrospun PVP thickness and the stirring speed were tested. Figure 8(a) and 
8(b) show the time required for capsule separation with respect to various 
electrospinning time for the PVP interlayer (1h, 1.5h, 2h, 2.5h) and different stirrer 
rotational speeds (300 rpm, 500 rpm and 700 rpm) mimicking the gastrointestinal 
motility, respectively. The results indicated that the separation time decreased as the 
thickness of ES interlayer increased and the stirrer speed increased. Increasing the PVP 
mass did not increase the time required for separation but decrease the dissolution time, 
which was incongruent with our expectation. To confirm this result, loss of PVP 
interlayer mass was recorded during the capsule separation process and is graphed in 
Figure 8(c). These result show that the entire PVP layer disappeared from the capsule 
within almost 10 min. For three different ES times to prepare the PVP interlayer (1.5h, 
2h, 2.5h), more than 90% of the PVP mass was lost from the capsule in 3min. The rate 
of mass loss of the PVP from the capsule increased with increasing PVP electrospinning 
time. Although the mass of the PVP increased (21.48±5.1, 34.32±4.9, 44.56±9.1, 
54.56± 10.8 mg), the effect of this increasing mass on the dissolution time could be 
neglected arising from the huge surface areas of electrospinning fibers and assuming 
perfect water absorption by the PVP. However, the increased thickness of the PVP 
interlayer that accompanied any mass increasing can provide more space between the 
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inn layer and outer layer for the PVP to dissolve due to increasing the wettable surface 
area. The whole separation time included the time for the PVP to dissolve between the 
two PCL fiber layers. Meanwhile, the interaction between the two PCL fiber layers 
played an important role during the separation process especially when the thickness of 
the PVP interlayer is small. Therefore, increasing the mass of the PVP interlayer would 
not prolong the dissolution and separation times, but the increasing the thickness of 
PVP interlayer could decrease any electrostatic interaction forces between the inner 
PCL-APAP layer and outer PCL-CM layer.  
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Figure 8. (a) Graph of dissolution time with different electrospinning time (1h, 1.5h, 2, 
2.5h). (b) Graph of dissolution time with various rotating speed of magneton (300 rpm, 
500 rpm, 700 rpm). (c) Percentage of PVP mass loss in the four sample groups with 
different electrospinning times. 
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3.7 In vitro release of drugs  
The drug release profile of the APAP and CM from the various composite capsules 
was investigated in a simulated gastric fluid (pH=1.7) and simulated intestinal fluid 
(pH=7.4) at 37℃ temperature to mimic conditions within the human body. Sample S1, 
S2 and S3 were selected to identify the influence of the interlayer thickness on the drugs’ 
release profile. Each test was carried out in triplicate. The drug release profiles are 
plotted in Figure 9. The release profile of APAP was generally faster than CM. The 
whole release profile went through a fast release period in the first 30 min and then a 
slow release period. The fast release period could be attributed to the drugs being 
attached to the surface of the fibers, as showing in the Raman false color mapping. 
Furthermore, the porous structure on the surface of the PCL fibers, as seen on the SEM 
images, increased the specific surface area which increased the area for interaction with 
the drugs59-60.  
Figure 9(b) presents the release profile of APAP and CM in the first 2 hours in detail. 
The tiny difference in release characteristics between these two drugs arise from 
differences in the cylinder structures. The release of APAP was faster than CM during 
the first 2 hours. The cumulative release of APAP was more than 90% while the 
cumulative release of CM was around 70%. This may be that the f APAP dissolves more 
easily than CM in an acidic condition. For the release profile of APAP loaded into the 
inner layer PCL fibers in different capsule structures, the increasing interlayer thickness 
increased the release rate possibly due to more space provided for drugs to diffuse into 
the liquid environment. The difference in interlayer thicknesses seemed to greatly 
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influence the release rate of the CM. However, above a certain ES thickness, the release 
rate of the drugs was not faster. This might be related to the fiber diameters since the 
diameter of the PCL-CM fiber was larger than PCL-APAP fiber, on average. 
The measured release rates were fitted to zero-order, first-order, the Higuchi, the 
Korsmeyer-Peppas and the Hixson-Crowell models to determine the mechanism of 
drug release. The results of the fitting parameters with regression coefficients and n 
value are shown in Table 2. The regression coefficients from modeling of the APAP 
reflects that the release process is more suitable to a first-order model and a Higuchi 
model, which describes the release profile of water-soluble pharmaceuticals in porous 
fibers61. The sample S1 without an interlayer was better fitted to a zero model and a 
first-order model. For CM, the Higuchi model was the best fit. As for the Korsmeyer-
Peppas model, it is not suitable in this situation because the cumulative drugs release 
reached and surpassed 60% in a short time. This result reflected that the appreciable 
quantity of drugs attached to the surface of the fibers which dissolved quickly in the 
liquid environment within the first several minutes. Therefore, the best fit for the drug 
release profiles for both APAP and CM from the composite capsules is the Higuchi 
model. In this work, two types of drugs can be encapsulated into the different 
components of the capsule and whose release rates can be controlled by the capsule 
thickness and the polymer combination. Also, the different release rates of the drugs 
are affected by the pH values of the gastrointestinal fluids. Thus, fast or long-term 
sustained release can simultaneously be achieved for acute treatment of symptoms 
while also decreasing the total number of daily doses. 
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Figure 9. (a) Drugs release profile of APAP and CM from the various capsule 
configurations in a simulated gastric fluid (pH=1.7) and a simulated intestinal fluid 
(pH=7.4). (b) Detailed drug release profile for APAP and CM from the composite 
capsule in the first two hours in a simulated gastric fluid (pH=1.7). 
 
Table 2. Fitting Parameters for APAP and CM in the first 80% of drug release from the 
capsule with respect to several models. 
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Drugs Zero-
order (R2) 
First-
order (R2) 
Higuchi 
(R2) 
Korsmeyer-
Peppas (R2) 
n 
value 
S1-APAP 
S2-APAP 
S3-APAP 
S1-CM 
S2-CM 
S3-CM 
0.99 
0.88 
0.93 
0.91 
0.79 
0.85 
0.96 
0.97 
0.98 
0.97 
0.83 
0.90 
0.92 
0.99 
0.99 
0.99 
0.94 
0.98 
0.76 
- 
- 
- 
- 
- 
0.01 
- 
- 
- 
- 
- 
 
3.8 Biocompatibility 
Test for biocompatibility were carried out to identify the practical use of the 
composite capsule for oral delivery. L929 cells were cultured with PCL-APAP fibers, 
PCL-CM fibers and a partial capsule, respectively. Results are shown in Figure 10(a) 
with blue stains showing the live cell nucleus and the red cytoskeleton and indicates 
good biocompatibility. The L929 cells adhered to the fibers and maintained their 
morphology. Compared to cells adhering to PCL-APAP fibers, the number of cells 
sticking to the PCL-CM fibers was less and the morphology of these cells was not very 
plump, which was attributed to the cytotoxicity of CM62. Cytotoxicity of the capsule 
and its components were carried out and this result is shown in Figure 9(b). The results 
show cell proliferation after adding capsules into the L929 cells culture dish. 
Meanwhile, cell culturing showed that cell viability with PCL-CM fibers was lower 
than with other capsule components. Thus CM had an effect on cell proliferation, and 
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the dose of CM in the capsule should to be decreased or limited.  
 
 
Figure 10. (a) Fluorescent micrographs of L929 cells cultured with capsule 
components PCL-APAP fibers and PCL-CM fibers and a partial capsule, respectively, 
after 2 days. (b) Cytotoxicity results with respect to each capsule components and the 
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cylindrical capsule. 
 
4. CONCLUSIONS 
In summary, a separating oral capsule comprised of multicomponent fibers loaded 
with synergistic drugs was designed and fabricated via a combined EHD 3D printing 
and ES process. The capsule structurally is comprised of three concentric cylindrical 
layers: an inner layer of PCL-APAP fibers that were EHD printed, an interlayer of PVP 
that was electrospun and an outer layer of PCL-CM fibers that were EHD printed. Two 
different drugs, APAP and CM in amorphous form, are loaded into the PCL layers. 
Mechanical test indicts that capsule possess well mechanical properties. The two PCL 
fiber layers successfully separated after the PVP interlayer dissolved. Increasing the 
PVP interlayer thickness should promote quicker separation of the inner layer and outer 
layer. The incorporation of Fe3O4 nanoparticles provides an opportunity for targeted 
release of the separate cylinders and for MRI imaging applications. In vitro testing of 
the release of the two drugs indicts that the release of APAP and CM from the porous 
fibers mostly fit the Higuchi model and this composite capsule is biocompatible based 
on tests with L929 cell cultures. 
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